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Introduction: Intensive care-acquired weakness is a
common problem, leads to significant impairment in
physical functioning and muscle strength, and is
prevalent in individuals with sepsis. Early rehabilitation
has been shown to be safe and feasible; however,
commencement is often delayed due to a patient’s
inability to co-operate. An intervention that begins early
in an intensive care unit (ICU) admission without the
need for patient volition may be beneficial in attenuating
muscle wasting. The eRiCC (early rehabilitation in critical
care) trial will investigate the effectiveness of functional
electrical stimulation-assisted cycling and cycling alone,
compared to standard care, in individuals with sepsis.
Methods and analysis: This is a single centre
randomised controlled trial. Participants (n=80) aged
≥18 years, with a diagnosis of sepsis or severe sepsis,
who are expected to be mechanically ventilated for ≥48 h
and remain in the intensive care ≥4 days will be
randomised within 72 h of admission to (1) standard
care or (2) intervention where participants will receive
functional electrical muscle stimulation-assisted supine
cycling on one leg while the other leg undergoes cycling
alone. Primary outcome measures include: muscle mass
(quadriceps ultrasonography; bioelectrical impedance
spectroscopy); muscle strength (Medical Research
Council Scale; hand-held dynamometry) and physical
function (Physical Function in Intensive Care Test;
Functional Status Score in intensive care; 6 min walk
test). Blinded outcome assessors will assess measures at
baseline, weekly, at ICU discharge and acute hospital
discharge. Secondary measures will be evaluated in a
nested subgroup (n=20) and will consist of biochemical/
histological analyses of collected muscle, urine and
blood samples at baseline and at ICU discharge.
Ethics and dissemination: Ethics approval has been
obtained from the relevant institution, and results will be
published to inform clinical practice in the care of
patients with sepsis to optimise rehabilitation and
physical function outcomes.




▪ Early rehabilitation is now advocated for indivi-
duals who are at risk of developing intensive
care unit acquired weakness (ICUAW).
▪ Can FES(functional electrical stimulation)-assisted
cycling or cycling alone minimise muscle mass
and strength reductions, and improve discharge
physical function, compared with standard care in
patients with sepsis?
▪ What are the cellular and molecular mechanisms
responsible for muscle changes in this patient
population, and can these be attenuated using
FES cycling or cycling alone?
Key messages
▪ This protocol outlines a randomized controlled
trial (RCT) that will investigate the effectiveness
of an FES-assisted cycling intervention and
cycling alone, commencing within 72 h of ICU
(intensive care unit) admission compared to
standard care.
▪ The results of this trial will provide data to guide
the early rehabilitation treatment of patients with
sepsis.
▪ Muscle biopsies and biomarker analyses will
provide insights into the effects of sepsis, and
an intensive care admission, and early rehabilita-
tion on intracellular signalling pathways and
histochemical changes responsible for muscle
mass losses.
Strengths and limitations of this study
▪ This is the first time that FES-assisted cycling
has been investigated within the ICU within 72 h
of admission with sepsis.
▪ This study combines bench-side research (biop-
sies and biomarker analyses) with patient-centred
outcomes (strength and physical function).
▪ It is a single centre trial so results may need to
be generalised with caution.




Intensive care-acquired weakness (ICUAW) is a common
problem following an ICU admission1–3 and is associated
with prolonged hospitalisation, delayed weaning and
increased mortality.4–6 Up to 25% of patients requiring
mechanical ventilation (MV) for greater than 7 days
develop ICUAW,1 and this figure may rise to 50–100% in
the septic population.7 8 Long-term follow-up studies of
survivors of critical illness have demonstrated signifi-
cantly impaired health-related quality of life9 10 and
physical functioning11–14 up to 5 years after ICU dis-
charge, with weakness being the most commonly
reported physical limitation.12 While survival has been a
main focus of intensive care research, there is a para-
digm shift to investigating methods to improve other
patient-centred outcomes.15 There has been an
increased awareness worldwide of the potential impact
and benefit of early rehabilitation in the ICU.15–19 Early
rehabilitation in the form of mobilisation has been
shown to be safe and feasible;20–24 however, it relies on
the patient being co-operative, and to have sufficient car-
diorespiratory reserve and medical stability25 to partici-
pate in therapy.
Muscle mass is known to reduce by at least 1.6% per
day,26 with a 16–20% reduction in muscle mass within the
first week in critically ill individuals with severe sepsis,27
indicating that interventions to attenuate muscle wasting
in this initial stage may be beneficial. The musculoskel-
etal system is a highly plastic and adaptive system,
responding quickly to changes in the demands placed
upon it.3 28 29 The pathogenicity and molecular mechan-
isms for ICUAW have primarily been extrapolated from
animal and in vitro muscle wasting models3 30–33 with ubi-
quitin−proteasome-mediated breakdown postulated to
be primarily responsible for the muscle loss observed in
critically ill individuals.30 34–36 Local and systemic inflam-
matory processes, which occur in critically ill individuals,
are thought to lead to a disruption in the balance
between muscle protein synthesis and protein break-
down, leading to an overall reduction in muscle mass and
force generation capacity.30 37 Increased circulating
inflammatory cytokines (eg, TNF-α and IL-1β) may drive
mitochondrial oxidative stress and increase intracellular
calcium, which are postulated to trigger muscle proteo-
lytic pathways30 38 and may interfere with insulin signal-
ling leading to anabolic resistance,39 and contribute to
electrophysiological inexcitability of the muscle.40 Recent
clinical trials in critically ill individuals have demon-
strated a reduction in muscle myofibre size with preferen-
tial proteolysis of the thick myosin filaments,41 42 with
one trial demonstrating a dramatic increase in protein
degradation of up to 160%.42 Currently, the pathogenesis
of ICUAW is poorly understood given limited research
within human clinical trials.2 30 Establishing the cellular
and molecular mechanisms responsible for loss of muscle
mass and strength is essential to help develop future
medical and physical therapies.
There is growing interest in the use of assistive technolo-
gies to enable patients to commence therapy early in an
ICU admission.43 Supine cycle ergometry, which can be
utilised passively, actively (by patient effort) or active
assisted (using electrical stimulation)16 has been studied in
ICU within one trial with promising results.16 However, the
intervention did not begin until at least 1-week post admis-
sion and there were no data reporting frequency of active
versus passive cycling.16 Neuromuscular electrical stimula-
tion (NMES) creates passive (ie, non-volitional) contrac-
tion of skeletal muscles through the use of low-voltage
electrical impulses delivered through to the skin to under-
lying muscle via surface electrodes.43 It can be com-
menced early, without the need for patient participation
and has been shown to prevent skeletal muscle atrophy in
healthy individuals44 and improve physical function and
strength in chronic disease populations, such as heart
failure and chronic obstructive pulmonary disease.45 To
date, studies within the ICU have involved stimulation of
only isolated muscle groups such as the quadriceps, or
peroneal muscles, in a resting non-functional position
using NMES, with conflicting findings.27 46–50 Further
rigorous research needs to be conducted to determine the
optimal stimulation settings, and efficacy of these interven-
tions particularly post ICU on muscle strength and phys-
ical function, which is being investigated in one trial
currently underway in the USA.51
Functional electrical stimulation (FES) is different to
NMES, as it recruits muscles in functional patterns
stimulating them in a similar way to how the muscles
would ‘normally’ contract under volitional control in
healthy individuals. For FES, the majority of the litera-
ture to date has been developed within the chronic
stroke52 and spinal cord injury (SCI) populations.53
Alternating recruitment of several muscle groups in a
functional activity, such as cycling has been demon-
strated in a chronic SCI population to improve the
length of time a contraction can be sustained, prior to
reaching the point of fatigue.54 This may enable patients
to train for a longer period of time, thereby enhancing
the training effect. FES-assisted cycling may influence
muscle strength and physical function not only at ICU
discharge, but also at acute hospital discharge. This trial
seeks to examine the combined effect of FES-assisted
cycling on muscle mass, strength, and physical function,
and compare this with cycling alone, and standard care.
Objectives
The primary objectives are to:
1. Evaluate the effectiveness of FES-assisted cycling and
cycling alone compared with standard care on
muscle mass/cross-sectional area, strength and phys-
ical function, in individuals admitted to ICU with
sepsis.
2. Evaluate the effectiveness of FES-assisted cycling
compared with cycling alone, on muscle mass,
muscle architecture, strength and physical function
in individuals admitted to ICU with sepsis.
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The secondary objectives are to:
1. Establish the intracellular signalling pathways and
histochemical changes responsible for muscle mass
losses in individuals with sepsis.
2. Inform decisions about outcome measures and
power calculations for future studies.
Hypotheses for the primary aims
H1. Patients who undergo FES-assisted cycling and
cycling alone compared with standard care will
have improved muscle mass/cross-sectional area,
strength and physical function.
H2. Patients who undergo FES-assisted cycling when com-
pared with cycling alone will have greater improve-
ment in muscle mass, strength and physical function.
H3. Patients in the intervention group will have
improved activity of anabolic signalling pathways
when compared with patients receiving standard
care as demonstrated from biomarker analysis.
METHODS
Trial design
This is an assessor blinded randomised controlled trial
(RCT) which will be conducted at Austin Health in
Melbourne, Australia.
Participants
Inclusion and exclusion criteria: Eighty participants in ICU
(Austin Health, Melbourne, Australia) meeting the eligi-
bility criteria will be recruited. Inclusion Criteria: (1)
≥18 years, (2) expected MV>48 h with diagnosis of
sepsis or severe sepsis as defined by ACCP Consensus
Conference Criteria55 and (3) predicted ICU LOS
≥4 days. Exclusion Criteria: (1) known primary systemic
neuromuscular disease or intracranial process at admis-
sion; (2) lower limb amputation/s; (3) unable to
perform study physical outcome measures premorbidly
due to condition impairing mobility; (4) assessed by
medical staff as approaching imminent death or with-
drawal of medical treatment within 36 h; (5) pregnancy;
(6) BMI>40; (7) presence of external fixator or superfi-
cial metal in lower limb; (8) open wounds or skin abra-
sions at electrode application points; (9) presence of
pacemaker or implanted defibrillator; (10) transferred
from another ICU after >2 days of consecutive MV; (11)
platelets<40 000 and INR>1.6 (for biomarker subgroup).
Recruitment timeframe
This study will take place in a single centre tertiary
20-bed ICU over an 18-month period. The ICU has a
throughput of 2100 patients per year with 200 patients/
year who are both septic and requiring MV for >48 h.
Recruitment and randomisation
Patients meeting the above criteria will be invited to par-
ticipate. Written informed consent from the patient,
next of kin (NOK) or substitute decision maker will be
sought. Participants will be asked to provide ongoing
consent when able. Participants will be randomly
assigned [1 : 1] to receive either standard care or the
intervention using offsite-independent randomisation.
Concealed allocation will be performed using sequen-
tially numbered opaque sealed envelopes only accessible
by research personnel with no involvement in the trial.
Intervention arm: leg allocation will be randomly allo-
cated [1 : 1] to FES-assisted cycling or cycling alone.
This trial involves a two-tier consent process first to the
FES-assisted cycling intervention and then additionally to
biomarker analysis and muscle biopsies with a nested sub-
group (n=20) within the primary trial. Details of all parti-
cipants who refuse consent to muscle biopsy will be
recorded. Information regarding screening and flow
through this trial will be reported according to the
CONSORT (Consolidated Standards of Reporting Trials)
Extended Non-Drug guidelines.56 This trial has been
approved by the Human Research Ethics Committee,
Austin Health and registered with the Australian and
New Zealand Clinical Trials Registry Identifier:
ACTRN12612000528853.
Procedure
The planned flow of participants throughout the study is
provided in figure 1. Once consent is obtained, and
prior to randomisation; participants will be referred to a
physiotherapist who will administer baseline testing of
muscle mass/cross-sectional area (CSA) using diagnostic
ultrasound (US) and body composition analysis. Once
the patient is awake, a blinded outcome assessor will
assess baseline strength and physical function once per
week. ‘Wakefulness’ is defined as being able to follow >3
of 5 commands as assessed by the De Jonghe’s readiness
scale1 with a Riker Sedation Agitation Scale (SAS) of
3–5.57 Biomarker assessment involving muscle biopsies,
urine and blood analyses will be assessed at baseline and
ICU discharge only. Attrition will be monitored and
reasons for withdrawal will be recorded in each trial arm
within figure 1.
Standard care
Both groups will receive usual medical and nursing
care in the ICU and ward settings. In the ICU, physio-
therapy will be administered according to a standar-
dised protocol, developed from a previous trial at the
same institution. Patients in both arms will undergo
usual care physiotherapy including respiratory and
mobilisation/rehabilitation.20 Mobilisation activities
(including those used for the benefit of the respiratory
system) will be provided for up to but not more than
15 min. Where possible the level and type of exercise
delivered, will be prescribed using the initial PFIT
results for each individual patient as per standard
care.58 Details of physiotherapy treatment will be
recorded but not protocolised on the acute hospital
ward.
Parry SM, Berney S, Koopman R, et al. BMJ Open 2012;2:e001891. doi:10.1136/bmjopen-2012-001891 3
The eRiCC trial – early rehabilitation in critical care
Intervention
The intervention will start within 72 h of ICU admission,
continuing until ICU discharge. Participants will under-
take up to 1 h of supine cycling daily, ≥5 times weekly
using a supine cycle ergometer (RT-300 supine model
Restorative Therapies, Ltd, Baltimore, Maryland, USA)
attached to a six-channel stimulator (SAGE stimulator,
Restorative Therapies Ltd, Baltimore, Maryland, USA)
and two RT50 wireless stimulator channels. Surface elec-
trodes will be applied to the gluteal, hamstrings, quadri-
ceps and calf muscles on both legs. However, the cycling
only leg will not have the electrodes switched on (sham).
The intensity of muscle stimulation will be delivered at
a level able to cause visible contractions (confirmed by
palpation if uncertain) in all muscle groups without
causing undue pain or discomfort to the participant.
Pain levels will be closely monitored during and post
each intervention session (box 1). If no contractions can
be elicited this will be recorded, but the treatment con-
tinued, and palpation for contraction assessed at 5 min
intervals. FES intensity will be gradually increased to a
maximum of 140 mA; with pulse duration of 300−400 μs;
frequency between 30 and 50 Hz; and a pedal cadence
between 30 and 45 rpm. Stimulation parameters will be
Figure 1 Consort diagram giving flow of participants throughout the study.
Abbreviations: FES-cycling, functional electrical stimulation-cycling; ICU, intensive care unit; MV, mechanical ventilation; n, number.
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adjusted to achieve the best possible muscle contraction
for the patient. Once the patient is more alert, and able
to participate, they will be provided with standardised
encouragement to engage in therapy. To increase the
intervention workload, resistance (N m) will be increased
incrementally and cycling cadence up to a maximum of
45 rpm. If a participant is readmitted to intensive care,
the intervention will be re-instigated until discharge to
the acute ward.
Blinding
While participants and intervention physiotherapist
cannot be blinded to group allocation, outcome asses-
sors and data analysts will be blinded to group alloca-
tion. The success of blinding will be assessed using a
short outcome assessor questionnaire for each time
point and the number of ‘unblinding’ episodes will be
recorded. If an assessor becomes unblinded, an alter-
nate assessor who is ‘blinded’ will continue to do the
measures for that particular individual.
OUTCOME MEASURES
Table 1 provides a summary of the outcome measures
and the time-points at which they will be assessed. All
primary outcome measures will be measured at baseline;
weekly while in ICU; at ICU discharge; and acute hos-
pital discharge.
Baseline descriptive data collection will include age,
gender, social, working and smoking history, admission
diagnosis, hand/leg dominance, comorbidities as deter-
mined by the Functional Comorbidity Index and Charlson
Comorbidity Index, severity of illness scoring and SAS
Score. Additionally number of days of sedation and nutri-
tional parameters, will also be recorded. ICU LOS, ICU
free days at day 28, MV hours, tracheostomy requirement,
incidence of ICU readmission, acute hospital LOS, dis-
charge destination and mortality will also be recorded.
PRIMARY OUTCOME MEASURES
Muscle mass
1. Bioelectrical impedance spectroscopy (BIS): Participants
will undergo measurement of body composition
Table 1 Summary of outcome measures and time points of assessment
Baseline Weekly in ICU ICU discharge Acute hospital discharge**
Muscle composition and thickness measures
Bioimpedance spectroscopy ✓ ✓ ✓ ✓
Quadriceps ultrasonography ✓ ✓ ✓ ✓
Strength measures
MRC score ✓ ✓ ✓
HHD grip and quadriceps ✓ ✓ ✓ ✓
Physical function measures
PFIT ✓ ✓ ✓
FSS-ICU score ✓ ✓ ✓
6-MWT ✓
Biomarker measures
Muscle biopsy ✓ ✓
Urine analyses ✓ ✓ ✓
Blood analyses ✓ ✓ ✓
FSS-ICU, functional status score in intensive care; HHD, hand-held dynamometry; MRC, medical research council; PFIT, physical function in
intensive care test; 6-MWT, six minute walk test.
** If patient is unable to walk >10 m unaided or with usual gait aid, ICU discharge measures will be completed at this time-point.
Box 1 Safety guidelines for exercise
Safety guidelines: exercise should not be delivered or should be
ceased when:
1. Patient mean arterial blood pressure <65 or below target
pressure.
2. Patient heart rate is <50 or >140 beats/min or new arrhyth-
mia develops (including ventricular ectopics or new onset
atrial fibrillation).
3. Patient requires >30 µg of noradrenaline or comparable
inotropic or vasopressor support.
4. Patient complains of new onset chest pain.
5. Patient becomes pale or sweaty and/or patient specifically
requests to stop due to feeling acutely unwell.
6. Presence of extracorporeal membrane oxygenation or intra-
aortic balloon pump.
7. FiO2>0.8.
8. PEEP>15 cm H2O.
9. Respiratory rate >35 breaths/min sustained for >60 s.
10. spO2 falls >10% below resting level or <85% for >60 s.
11. Numerical rating scale (NRS) pain level remains >7 for 5 min
despite adjusting stimulation intensity. Pain levels will be
monitored using NRS if patient is awake at commencement
and 5 mins into the exercise session. If the patient is intu-
bated we will use standardised assessment of pain including
facial grimacing, ventilator dysinchrony, and agitation levels
to monitor pain levels during exercise.
FiO2, Fraction of inspired oxygen; mm Hg, millimetres of mercury;
µg, micrograms; NRS, Numerical Rating Scale; PEEP, Positive
end expiratory pressure; spO2, saturation of peripheral oxygen.
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using multi-frequency BIS machine (ImpediMed
SFB7, ImpediMed Ltd, Brisbane, Australia). This will
enable calculation of total body water, extracellular
and intracellular fluid as well as fat-free mass, and an
estimate of muscle mass.59 Measurements will be
taken in triplicate with participants in the supine pos-
ition after single use dual tab gel electrodes have
been placed on one foot and one hand on the same
side.60 All data will be uploaded onto the BioImped
software (BIS) for subsequent analysis. The reliability
of this device in both the critically ill and healthy
populations has previously been established61 and
numerous investigators have established the validity
of the BIS in detecting within subjects change over
time in septic and postsurgical populations.62 63
2. Diagnostic two-dimensional (2D) ultrasonography (US) of
quadriceps muscle: Rectus Femoris and Vastus
Intermedius CSA and thickness will be measured
using diagnostic US (Voluson e BT09 Ultrasound,
GE Healthcare, Yokogawa Medical Systems Ltd,
Japan). Participants will lie in supine with their leg
in passive extension and neutral rotation. A water-
soluble transmission gel will be applied to the US
head to allow acoustic contact, without depressing
the dermal surface. The scanning head will be
applied perpendicular to the long axis of the thigh
on its anterior surface, approximately three-fifth dis-
tance from anterior superior iliac spine to the super-
ior patellar border.64 The point will be marked for
consistency of US probe location. Measures will be
made in triplicate and averaged. The same operator
who is experienced in the measurements will
perform all US examinations. For supplementation
of muscle thickness measurements, circumference
of the thigh will be assessed using a tape measure at
the US measurement site. Reliability and validity of
ultrasonography have previously been established
both in septic and other medical populations.65–67
Muscle strength
1. Medical Research Council Scale (MRC): manual muscle
testing will be scored using the six point MRC scale.68
2. Hand-held dynamometry (HHD): Hand grip and quadri-
ceps strength (supine with 5-inch bolster under knee to
enable flexion)69 will be assessed using HHD bilaterally
using a Commander PowerTrack II Dynamometer
1500 (Banner Therapy Ltd, Asheville, North Carolina,
USA) and a Jamar Dynamometer (Sammons Preston
Rolyan, Bolingbrook, Illinois, USA), respectively. HHD
has established reliability and validity.69 70
Physical function
Will be assessed using several different methods:
1. ‘PFIT’ (Physical Function Independence Test)71
2. ‘FSS-ICU’ (Functional Status Score in ICU)72
3. The ‘six minute walk test’ (6-MWT) is a commonly
used test, which measures the distance that a patient
can walk quickly in 6 min over a 25 m flat hallway. It is
both self-paced and sub-maximal. The 6 MWT has
previously been used in the ICU population. This test
will only be performed at acute hospital discharge.73
SECONDARY OUTCOME MEASURES
Biomarker analysis
Participants who consent to participation will also be
approached for consent to biomarker assessment involv-
ing muscle biopsies, blood and urine samples. Within the
intervention arm as previously described, one leg under-
goes cycling alone and the other FES-assisted cycling.
Therefore, muscle biopsies will be collected from both
lower limbs in the intervention arm, and in one lower
limb in the standard care arm, to allow comparison
across the groups. Biomarker assessment will be per-
formed at baseline, and at ICU discharge (where possible
the ‘ICU discharge’ measure will occur 24 h post final
intervention exercise session).
Muscle biopsy
Using an aseptic technique, under local anaesthetic
injected into the skin and fascia, muscle biopsies
(100–200 mg of tissue) will be obtained from the vastus
lateralis muscle, 10 cm above the patella. Prior to biop-
sies being performed, senior medical staff will review
anticoagulation profiles, and using the Bergstrom percu-
taneous needle technique under suction74 will perform
biopsies. Once the tissue has been extracted, part of the
biopsy sample (20–50 mg) will be dissected carefully,
freed from any visible non-muscle material, embedded
in Optimal Cutting Temperature (OCT) compound and
immediately frozen in liquid nitrogen-cooled isopentane
and stored at −80°C until histochemical analyses. The
remainder of the biopsy (100–150 mg) will be immedi-
ately frozen in liquid nitrogen and stored at −80°C, until
further analyses. Histological assessments of muscle
structure and infiltration of inflammatory cells, will be
performed using H&E staining, and examination of
muscle fibre-type-specific changes in cross sectional
area, oxidative capacity, substrate stores, satellite cell acti-
vation and key proteins regulating protein synthesis and
breakdown (mTOR, AMPK, MURF-1 and MAFbx).75
mRNA and protein expression levels and phosphoryl-
ation status of key signalling proteins in the regulation
of inflammation will be determined using RT-PCR and
standard immune-blotting techniques, respectively.76
Urine analysis
Twenty-four hour urine samples will be collected for ana-
lysis of urinary creatinine, 3-methylhistidine (3-MH) and
urea levels. The samples will be stored at −80°C until
analysis. 3-MH will be analysed using high-performance
liquid chromatography (HPLC).
Blood analysis
Venous blood (15 ml) will be collected at each time
point and processed to obtain plasma and serum for
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subsequent analyses. Stored plasma and serum will be
analysed using ELISA methods for IGF-1, IL-1β, IL-6,
IL-10, IL-18 and TNF-α. Blood levels of C-reactive
protein (CRP), urea and creatinine will be retrieved
from the standard intensive care nursing charts over a
24-h period. HPLC will be performed to analyse vitamin
D levels, serum amino acid concentration levels and
3-MH levels.
SAFETY PROTOCOLS
All physiotherapists providing intervention and outcome
measurements are experienced ICU clinicians trained in
safety and basic life support. Written manuals of proto-
cols and safety guidelines will be made available to all
research personnel. Criteria for commencing and
ceasing exercise or outcome measurement are outlined
in box 1.
If any adverse event occurs either during, or up to an
hour following intervention or outcome measurement,
the chief investigators will be notified. Serious adverse
events are defined in this trial as ‘adverse events’, which
results in death, cardiac arrest or stroke. These events
will be reported to the Austin Health HREC. A data
monitoring committee will examine trial safety by review-
ing any adverse events at regular intervals. Research per-
sonnel to identify potential safety, recruitment, and
treatment issues will review data process indicators based
on the consort diagram monthly.
STATISTICS
Sample size calculation
The sample size calculation is informed by data from
Burtin et al16 using the HHD improvement±SD for quad-
riceps strength of 0.54±0.76 N/kg. Using α=0.05 and
power=0.80 the total required sample size is 64 cases.
Allowing for 14% in hospital mortality and dropouts the
sample size has been increased to 80 cases. For bio-
marker analyses (primarily muscle biopsy) the sample
size calculation is based on prior trials detecting
changes in muscle protein synthesis and associated sig-
nalling following exercise, nutritional and pharmaco-
logical interventions (increase in signalling >20% with
SD in signalling of 2%).77 78 Using α=0.05 and
power=0.80 the required sample size is 18 cases. To
account for dropouts and mortality we have increased
this sample size to 20 cases.
Statistical analysis
All data will be entered into a purposefully designed
database and exported to IBM SPSS Statistical software
package (SPSS Inc, V.20, Chicago, Illinois, USA) for ana-
lyses. Descriptive statistics will first be used to examine
the distribution for the two groups comparing baseline
scores, to describe mean outcomes, and test whether
parametric test assumptions have been met. Analyses will
be by intention to treat. Statistical significance will be set
at p<0.05 (two-tailed). Possible differential attrition will
be assessed by comparing baseline characteristics of
those who withdraw or die against those who remain in
the trial. Linear mixed modelling will be used to assess
the treatment effects. Imputation of missing data will
not be undertaken. Adjustment will be undertaken if sig-
nificant imbalance is evident in baseline covariates and
in this case results of both the adjusted and unadjusted
results will be described.79 As a secondary analysis mean
change in scores, 95% CIs, and comparison with
minimal clinically important differences in outcomes
will be presented.
ETHICS AND DISSEMINATION
The Austin Health HREC has granted ethical approval
for this trial. Trial results will be disseminated widely,
through peer-review journal manuscripts and scientific
conference presentations. The investigators will submit
trial progress summaries to all sponsors of the trial on a
regular basis.
RESULTS
The trial will determine whether FES-assisted cycling, or
cycling alone compared to standard care will improve
muscle mass, strength and physical function. The cellu-
lar and molecular mechanisms, responsible for the
observed muscle mass and strength changes will be
examined using biomarker analyses.
DISCUSSION
ICU-AW is a well-recognised clinical problem especially in
individuals with sepsis. The effects of this syndrome have
been shown to last for many years, with physical function
one of the most affected patient outcomes. This research
is innovative in that it combines both clinical and basic
sciences to evaluate the mechanisms of change together
with measuring patient-centred outcomes. It will be the
first interventional trial to evaluate the effectiveness of
FES-assisted cycling and cycling alone on muscle mass,
architecture, strength and physical function. The import-
ant primary outcomes for the patient are expected to be
improved or maintained strength, and physical function.
Given the potentially devastating effects of a critical
illness on the survivors and their families,15 gaining
improved strength and physical function will be critical
outcomes for all ICU survivors. The study design will
allow future decisions to be made about sample sizes and
primary outcomes to inform future research. The evalu-
ation of an early rehabilitation programme involving
FES-assisted cycling, which can commence in the critical
period where the majority of muscle reductions occur,
may provide direction for the development of appropri-
ate rehabilitation in survivors of ICU.
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